Adult growth hormone deficiency Adult growth hormone deficiency
Conditions
Interventions
none
None
Sponsors
Kubo Haremaru
Eligibility
Inclusion criteria
Inclusion criteria: 1, Severe Adult growth hormone deficiency 2, Patients scheduled for Wegovy administration with an indication for its use, 3, BMI of 27 kg/m2 or higher with at least two obesity-related health disorders, or a BMI of 35 kg/m2 or higher 4, Receiving nutritional counseling for more than 6 months 5, Undergoing growth hormone replacement therapy
Exclusion criteria
Exclusion criteria: 1, Patients with severe trauma or undergoing surgery 2, Excessive alcohol consumers (estimated ethanol intake more than 30 g/day for men, and more than 20 g/day for women) 3, Patients with other liver diseases that cannot be ruled out, including viral hepatitis, autoimmune hepatitis, and drug-induced hepatitis 4, Patients with severe liver disfunction or liver cirrhosis classified as Child-Pugh B or C 5, Patients infected with the hepatitis virus 6, Patients with obvious malignant tumors 7, Pregnant women or women who might be pregnant 8, Patients using implanted medical devices (such as pacemakers) 9, Individuals under 20 years old or over 80 years old 10, Patients with intellectual disabilities or language problems that prevent them from fully understanding the study 11, Patients who are judged to be unable to carry out this study by the principal investigator or research assistant.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The change in hepatic fat content (MRI-PDFF) from the beginning to the end of the study | — |
Secondary
| Measure | Time frame |
|---|---|
| 1, The changes in parameters related to body composition from the beginning to the end of the study. 2, The changes in parameters related to each blood test item from the beginning to the end of the study. 3, The correlation between the change in MRI-PDFF and each parameter. | — |
Contacts
Public ContactHaremaru Kubo
Kitasato University Hospital
Outcome results
None listed